balixafortide

Peptideexperimental

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • pol6326
  • pol6326
  • pol-6326

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06981806Phase 1Jan 31, 2026Cedars-Sinai Medical Center
NCT04826016Phase 1/Phase 2 (Phase 2)Jul 31, 2021MedSIR, Quiron Group, Barcelona (Spain), University of Vermont
NCT03786094Phase 3Jun 14, 2019Polyphor Ltd.
NCT01905475Phase 2Jul 1, 2013Gottfried Wilhelm Leibniz Universität Hannover, Polyphor Ltd.
NCT01837095Phase 1Jun 1, 2013Polyphor Ltd.
NCT01413568Phase 1/Phase 2 (Phase 2)Apr 1, 2012Polyphor Ltd., University of Utah
NCT01841476Phase 1Feb 1, 2012J. W. Goethe University, Polyphor Ltd.
NCT01105403Phase 2Apr 1, 2009Polyphor Ltd., University of Heidelberg
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Polyphor Ltd.For profit6632009
Cedars-Sinai Medical CenterAcademic/Hospital1112026
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1012013
J. W. Goethe UniversityAcademic/Hospital1012012
MedSIRAcademic/Hospital1112021
Quiron Group, Barcelona (Spain)Academic/Hospital1012021
University of HeidelbergAcademic/Hospital1012009
University of UtahAcademic/Hospital1012012
University of VermontAcademic/Hospital1012021
9 organizations
Page 1 / 1